Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
James Wynn recently made a profit of approximately $40.87 million on BTC long positions

James Wynn recently made a profit of approximately $40.87 million on BTC long positions

星球日报星球日报2025/05/22 06:59
Show original

According to on-chain analyst Ember's monitoring, the whale James Wynn has started to reduce his position. In the past 20 minutes, he reduced his long position by 1,080 BTC, valued at $120 million. His current BTC position is as follows:
Holding 9,118 BTC long positions, valued at $1 billion, with an opening price of $108,065 and a liquidation price of $102,858, with an unrealized profit of $24.1 million.
In addition to the $16.77 million profit realized from reducing his position, his gains from going long on BTC in the past two days are approximately $40.87 million.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Just about three months after listing, two SK Hynix leveraged ETFs are set to be delisted in the United States.

Tradr ETFs announced that its two leveraged products linked to SK Hynix ADRs will be liquidated and delisted around November 12, with one being long and the other short. Despite only being listed for a few months, their combined scale has shrunk to about $1.3 million, down more than 60% from their peak. SK Hynix's Seoul stock price has fallen 56% from its high, similar products in the industry are generally under pressure, and South Korea has also further tightened regulations on leveraged products.

华尔街见闻•2026/10/26 05:56
Just about three months after listing, two SK Hynix leveraged ETFs are set to be delisted in the United States.

A $5 billion single-product emerges? JPMorgan maintains a "Neutral" rating on Amgen (AMGN.US): A good drug doesn't necessarily mean a good buying opportunity.

Amgen's Imdelltra has maintained data with an HR of 0.42, nearly doubling survival time. Morgan Stanley estimates that it will become a single product with annual sales of around 5 billions USD. However, they maintain a Neutral rating and a target price of 350 USD.

智通财经•2026/10/26 04:20
A $5 billion single-product emerges? JPMorgan maintains a "Neutral" rating on Amgen (AMGN.US): A good drug doesn't necessarily mean a good buying opportunity.